Patient Power®
Get Email Alerts!
Health Topics
Multiple Myeloma Health Center
Health Center Home Audio Programs Videos Conference Coverage
  • ASH 2011
    • Live Events
  • SCCA Myeloma Town Hall 2011
    • Search by Keyword:
    Search by Health Topic:
    View all Health Topics >
    Spring Survey 2012 Results

    Contemporary Issues in Relapsed-Refractory Myeloma

    PROGRAM DETAILS:

    Multiple Myeloma is the second most common hematologic malignancy and is characterized by malignant plasma cells that reproduce uncontrollably. These plasma cells tend to localize within the bone marrow, but they may also be found elsewhere in the body. In this special edition program, Dr. James Berenson joins Andrew to discuss contemporary issues in relapsed-refractory myeloma. Based in Los Angeles, Dr. Berenson is the Founder, President and Chief Executive Officer of the Institute for Myeloma and Bone Cancer Research. He has been involved in many of the major breakthroughs that have brought new treatments for patients with myeloma and resulted in improvements in the length and quality of their lives.

    Dr. Berenson speaks in depth about the distinguishing characteristics for each agent used for myeloma treatment, including Revlimid, Velcade (bortezomib), Dexamethasone, Doxil and others, as well as the effectiveness of these drugs in combination therapy. He explains the treatment-free interval, how to re-treat patients with a previous response to certain drugs, his unique take on maintenance therapy, and his approach to treating relapse patients. Hear the latest on Dr. Berenson’s opinion about bone marrow transplant and the debate surrounding it, as well as his answers to questions submitted by listeners.

    Listen to this program to learn why Dr. Berenson is so optimistic about multiple myeloma treatment. The rapid advances in research are helping those with multiple myeloma to live longer, better quality lives.

    Get Email Updates:

    Get updated automatically when new content about Multiple Myeloma has been posted.
    Privacy Policy
    Multiple Myeloma
    EXPERTS & GUESTS:
    James Berenson, M.D. James Berenson, M.D.
    Founder, President and Medical and Scientific Director, Institute for Myeloma and Bone Cancer Research
    James Berenson, M.D. is the Founder, President & Chief Executive Officer of the Institute for Myeloma and Bone Cancer Research. Dr. Berenson has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 25 years. He has been involved in many of the major breakthroughs that have brought new treatments for... more >

    TRANSCRIPT:

    1. Introduction
    2. Advances in Myeloma Treatment
    3. Treatment-Free Intervals
    4. The Debate Over Bone Marrow Transplant
    5. Treating After Relapse
    6. Combination Therapy: Velcade and Doxil
    7. Clinical Trials
    8. Treatment Side Effects
    9. Bone Disease and Bisphosphonates
    10. Chromosome 13 Deletion
    11. Living with Myeloma
    12. Maintenance Therapy
    13. Myeloma Specialists
    14. Kappa Lambda Ratio
    15. Histone Deacetylase Inhibitors
    16. Relapse Treatment
    17. The Future for Myeloma

    RELATED LINKS: